Genmab AS (GMAB)

47.06
+0.67(+1.44%)
After Hours
47.14
+0.08(+0.17%)
- Real-time Data
  • Volume:
    789,390
  • Day's Range:
    45.47 - 47.50
  • 52 wk Range:
    26.19 - 47.50
Trading near 52-week High

Genmab AS has hit the highest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

GMAB Overview

Prev. Close
46.39
Day's Range
45.47-47.5
Revenue
11.99B
Open
45.55
52 wk Range
26.19-47.5
EPS
86.43
Volume
789,390
Market Cap
30.16B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
587,885
P/E Ratio
38.48
Beta
0.713
1-Year Change
25.63%
Shares Outstanding
65,229,399
Next Earnings Date
22 Feb 2023
What is your sentiment on Genmab AS?
or
Market is currently closed. Voting is open during market hours.

Genmab AS Analysis

Genmab AS Company Profile

Genmab AS Company Profile

Employees
1445

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Read More

Analyst Price Target

Average41.43 (-11.96% Downside)
High53
Low33
Price47.06
No. of Analysts10
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong BuyStrong Buy
SummarySellStrong BuyStrong BuyStrong BuyStrong Buy